Chimeric Antigen Receptor (CAR) T-cell Persistence at Month 3 (M3) Predicts Clinical Outcomes in Adult Patients (pts) with Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (R/R B-ALL) Treated with Obecabtagene autoleucel (obe-cel)
Year: 2026
Type: article
Institutions: University College London, Memorial Sloan Kettering Cancer Center, Manchester Royal Infirmary, City Of Hope National Medical Center, Methodist Healthcare, Universitat Autònoma de Barcelona, Vall d'Hebron Hospital Universitari, Hospital Universitari i Politècnic La Fe, King's College Hospital NHS Foundation Trust, University of California, San Francisco, University of California, Davis, Autolus (United Kingdom), Moffitt Cancer Center, University of Chicago, Dana-Farber Cancer Institute, The University of Texas MD Anderson Cancer Center
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7127343352